CD79A and T-cell non-Hodgkin lymphoma: At immunohistochemistry, the prevalent cell immunoreactivity for B cell markers (CD20, CD79a, and PAX5) or for the T cell marker (CD3) was considered diagnostic for B cell (BCL) and T cell lymphoma (TCL), respectively.